Heather Marie Gibson (ax1572)
University information
Contact information
Cancer Biology Program
Assistant Professor
Barbara Ann Karmanos Cancer Institute
4100 John R, HWCRC 823
Detroit, MI 48201
Mark Gregory
Alexander Ullrich
James Glassbrook Graduated 2/15/2023 Biochemistry, Microbiology, Immunology
Justin Hackett Graduated 1/20/2023 Cancer Biology
Oncology
• Development of new immunotherapy strategies
• Regulation of T cell trafficking and activation in the tumor microenvironment (TME)
• Modulation of macrophages in the TME
• Imaging modalities to monitor immune activity in situ
Cancer immunotherapy breakthroughs have shown tremendous promise, but there remains an urgency to determine which patients will respond and why many do not. My lab uses functional genomics and genetically diverse animal models to pinpoint genes and/or pathways involved in immunotherapy resistance. We have discovered putative regulators of both immune checkpoint inhibitors and anti-tumor antibody, also known as targeted immunotherapy. The goal is to identify both biomarkers and actionable targets to improve clinical outcomes. Additionally, we have multiple ongoing collaborative projects aimed at developing new strategies to engage the immune system against cancer.
Pubmed link to all Publications
Allison V Mitchell, Ling Wu, C James Block, Mu Zhang, Justin Hackett, Douglas B Craig, Wei Chen, Yongzhong Zhao, Bin Zhang, Yongjun Dang, Xiaohong Zhang, Shengping Zhang, Chuangui Wang, Heather Gibson, Lori A Pile, Benjamin Kidder, Larry Matherly, Zhe Yang, Yali Dou, Guojun Wu. FOXQ1 recruits the MLL complex to activate transcription of EMT and promote breast cancer metastasis. Nature Communications 2022;13:6548.
Hackett J, Gibson H, Frelinger J, Buntzman A. Using the Collaborative Cross and Diversity Outbred Mice in Immunology. Curr Protoc. 2022;2:e547.
Wallace-Povirk A, Rubinsak L, Malysa A, Dzinic SH, Ravindra M, Schneider M, Glassbrook J, O'Connor C, Hou Z, Kim S, Back J, Polin L, Morris RT, Gangjee A, Gibson H, Matherly LH. Targeted therapy of pyrrolo[2,3-d]pyrimidine antifolates in a syngeneic mouse model of high grade serous ovarian cancer and the impact on the tumor microenvironment. Sci Rep. 2022;12:11346.
Viola NT, Glassbrook JE, Kalluri JR, Hackett JB, Wicker MN, Sternberg J, Gibson HM. Evaluation of an ImmunoPET Tracer for IL-12 in a Preclinical Model of Inflammatory Immune Responses. Front Immunol. 2022;13:870110.
Toupin N, Herroon MK, Thummel RP, Turro C, Podgorski I, Gibson H, Kodanko JJ. Metalloimmunotherapy with Rhodium and Ruthenium Complexes: Targeting Tumor-Associated Macrophages. Chemistry. 2022;28:e202104430.
Hackett JB, Glassbrook JE, Muñiz MC, Bross M, Fielder A, Dyson G, Movahhedin N, McCasland J, McCarthy-Leo C, Gibson HM. A diversity outbred F1 mouse model identifies host-intrinsic genetic regulators of response to immune checkpoint inhibitors. Oncoimmunology. 2022;11:2064958.
BS in Biochemistry and Molecular Biology (2004): Michigan State University, East Lansing, Michigan
PhD in Immunology (2011): Wayne State University, Detroit, Michigan
CB7210 Fundamentals of Cancer Biology
CB7300 Grant Writing Workshop
CB7410 Cancer Immunology and Immunotherapy (Course Director)
CB8920 Principles of Clinical and Translational Cancer Research
IM7010 Biomedical Immunobiology
IM7300 Molecular Biology of Viruses
PHC7410 Principles of Toxicology
CHM7680/6680 - Clinical and Molecular Aspects of Cancer
Oncology
Assistant Professor - Tenure Track
Basic Science
Karmanos Cancer Institute
Hudson-Webber Cancer Research Center - 823
4100 John R.
Detroit, MI 48201
Karmanos Cancer Institute
4100 John R. HW08AO
Detroit, MI 48201
313-576-8257
Education
(2011) Ph.D. Immunology, Wayne State University, Detroit, MI
(2004) B.S. Biochemistry & Molecular Biology, Michigan State University, Lansing, MI
Postgraduate Training
(2016-2018) Research Scientist, Department of Oncology, Wayne State University, Detroit, MI
(2014-2016) Research Associate, Department of Oncology, Wayne State University, Detroit, MI
(2014-2015) Innovation Fellowship Program, Wayne State University, Detroit, MI
(2011-2014) Post-Doctoral Fellow, Department of Oncology, Wayne State University, Detroit, MI
Faculty Appointments
(2018-Present) Assistant Professor, Department of Oncology, Wayne State University School of Medicine, Detroit, MI
(2016-Present) American Association of Immunologists
(2016-Present) European Academy for Tumor Immunology
(2012-Present) American Association for Cancer Research
(2021) College Teaching Award, Wayne State University School of Medicine
(2016) TRCCC Young Investigator Award, Translational Research Cancer Centers Consortium
(2015) AAI Young Investigator Award, American Association of Immunologists
(2014) AAI Young Investigator Award, American Association of Immunologists
(2013) TRCCC Travel Award, Karmanos Cancer Institute
(2012) TRCCC Travel Award, Karmanos Cancer Institute
(2010) 2nd place poster award, Translational Research Cancer Centers Consortium
(2005) Oral presentation winner, Henry Ford Health System Research Symposium
CB7210 - Fundamentals of Cancer Biology
CB7300 - Grant Writing Workshop
CB7410 - Cancer Immunology and Immunotherapy (Course Director)
CB8920 - Principles of Clinical and Translational Cancer Research
IM7010 - Biomedical Immunobiology
IM7300 - Molecular Biology of Viruses
PHC7410 - Principles of Toxicology
CHM7680/6680 - Clinical and Molecular Aspects of Cancer
Cancer immunotherapy breakthroughs have shown tremendous promise, but there remains an urgency to determine which patients will respond and why many do not. My lab uses functional genomics and genetically diverse animal models to pinpoint genes and/or pathways involved in immunotherapy resistance. We have discovered putative regulators of both immune checkpoint inhibitors and anti-tumor antibody, also known as targeted immunotherapy. The goal is to identify both biomarkers and actionable targets to improve clinical outcomes. Additionally, we have multiple ongoing collaborative projects aimed at developing new strategies to engage the immune system against cancer.
- Genetic regulation of immune response, particularly in the context of anti-tumor immunity.
- Development of new immunotherapy strategies.
- Regulation of T cell trafficking and activation in the tumor microenvironment (TME).
- Modulation of macrophages in the TME.
- Imaging modalities to monitor immune activity in situ.
Pharmacology
Barbara Ann Karmanos Cancer Institute
4100 John R, HWCRC 823
Detroit, MI 48201
313-576-8257
Cancer immunotherapy breakthroughs have shown tremendous promise, but there remains an urgency to determine which patients will respond and why many do not. My lab uses functional genomics and genetically diverse animal models to pinpoint genes and/or pathways involved in immunotherapy resistance. We have discovered putative regulators of both immune checkpoint inhibitors and anti-tumor antibody, also known as targeted immunotherapy. The goal is to identify both biomarkers and actionable targets to improve clinical outcomes. Additionally, we have multiple ongoing collaborative projects aimed at developing new strategies to engage the immune system against cancer.
BS in Biochemistry and Molecular Biology (2004): Michigan State University, East Lansing, Michigan
PhD in Immunology (2011): Wayne State University, Detroit, Michigan
Allison V Mitchell, Ling Wu, C James Block, Mu Zhang, Justin Hackett, Douglas B Craig, Wei Chen, Yongzhong Zhao, Bin Zhang, Yongjun Dang, Xiaohong Zhang, Shengping Zhang, Chuangui Wang, Heather Gibson, Lori A Pile, Benjamin Kidder, Larry Matherly, Zhe Yang, Yali Dou, Guojun Wu. FOXQ1 recruits the MLL complex to activate transcription of EMT and promote breast cancer metastasis. Nature Communications 2022;13:6548.
Hackett J, Gibson H, Frelinger J, Buntzman A. Using the Collaborative Cross and Diversity Outbred Mice in Immunology. Curr Protoc. 2022;2:e547.
Wallace-Povirk A, Rubinsak L, Malysa A, Dzinic SH, Ravindra M, Schneider M, Glassbrook J, O'Connor C, Hou Z, Kim S, Back J, Polin L, Morris RT, Gangjee A, Gibson H, Matherly LH. Targeted therapy of pyrrolo[2,3-d]pyrimidine antifolates in a syngeneic mouse model of high grade serous ovarian cancer and the impact on the tumor microenvironment. Sci Rep. 2022;12:11346.
Viola NT, Glassbrook JE, Kalluri JR, Hackett JB, Wicker MN, Sternberg J, Gibson HM. Evaluation of an ImmunoPET Tracer for IL-12 in a Preclinical Model of Inflammatory Immune Responses. Front Immunol. 2022;13:870110.
Toupin N, Herroon MK, Thummel RP, Turro C, Podgorski I, Gibson H, Kodanko JJ. Metalloimmunotherapy with Rhodium and Ruthenium Complexes: Targeting Tumor-Associated Macrophages. Chemistry. 2022;28:e202104430.
Hackett JB, Glassbrook JE, Muñiz MC, Bross M, Fielder A, Dyson G, Movahhedin N, McCasland J, McCarthy-Leo C, Gibson HM. A diversity outbred F1 mouse model identifies host-intrinsic genetic regulators of response to immune checkpoint inhibitors. Oncoimmunology. 2022;11:2064958.
• Genetic regulation of immune response, particularly in the context of anti-tumor immunity
• Development of new immunotherapy strategies
• Regulation of T cell trafficking and activation in the tumor microenvironment (TME)
• Modulation of macrophages in the TME
• Imaging modalities to monitor immune activity in situ
Courses taught by Heather Marie Gibson
Winter Term 2025 (future)
- IBS7090 - Biomedical Immunology
- IM7010 - Fundamentals of Immunology
- IM7030 - Molecular Biology of Viruses
Winter Term 2024
- IM7010 - Fundamentals of Immunology
- IM7030 - Molecular Biology of Viruses
- CB7210 - Fundamentals of Cancer Biology
- CB8920 - Principles of Translational and Clinical Cancer Research
- IBS7090 - Biomedical Immunology
Fall Term 2023
Winter Term 2023
- CB7210 - Fundamentals of Cancer Biology
- IM7010 - Fundamentals of Immunology
- CB8920 - Principles of Translational and Clinical Cancer Research
- IM7030 - Molecular Biology of Viruses
- IBS7090 - Biomedical Immunology
Spring-Summer Term 2022
Winter Term 2022
- CB7210 - Fundamentals of Cancer Biology
- IBS7090 - Biomedical Immunology
- IM7010 - Fundamentals of Immunology
- IM7030 - Molecular Biology of Viruses